

#### OFFICE OF THE ATTORNEY GENERAL CONNECTICUT

WILLIAM TONG ATTORNEY GENERAL

May 21, 2025

<u>By Email</u>

Re: Compounded GLP-1 Weight Loss Medications

Dear Healthcare Provider:

We are writing to put you on notice that our office is aware of conduct by certain Connecticut weight loss clinics, med spas, medical practices and other businesses, which may violate the Connecticut Unfair Trade Practices Act ("CUTPA").

Compounding pharmacies are no longer allowed by the FDA to manufacture semaglutide or tirzepatide weight loss injections (collectively, "GLP-1 Medications") in bulk because these medications are no longer on the FDA's shortage list.<sup>1</sup> The FDA has also identified multiple health and safety concerns associated with the use of compounded GLP-1 Medications, including dosing errors, compounding pharmacies' use of salt forms of semaglutide and/or tirzepatide, many of which are sourced from overseas manufacturers with spotty inspection records,<sup>2</sup> and multiple adverse event reports, some of which required medical intervention.<sup>3</sup>

Nevertheless, many healthcare providers who are licensed in Connecticut continue to advertise and prescribe compounded GLP-1 Medications. Some even advertise GLP-1 weight loss injections that contain additives, such as vitamins, or compounded semaglutide and tirzepatide pills. A handful of illustrative examples of this conduct are depicted below:

<sup>&</sup>lt;sup>1</sup> See FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize (April 28, 2025), available at <u>https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize</u> <sup>2</sup> See <u>https://www.brookings.edu/articles/the-wild-east-of-semaglutide/</u> ("[T]]hree Chinese firms responsible for 20% of reported

imported volume [of semaglutide] have never been inspected as of September 2024. Three additional Chinese firms, responsible for 44.5% of reported imported volume, were cited during their latest FDA [inspections] for CGMP [current good manufacturing practices] violations.").

<sup>&</sup>lt;sup>3</sup> See <u>https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss</u>


May 21, 2025 Page | 2



#### ABOUT THE SKINNY SHOT

### GET THAT WEIGHT LOSS SUPPORT YOU HAVE BEEN LOOKING FOR

The Skinny Shot is a medication that works decreasing appetite and signaling to the brain a feeling of fullness, or satiety. The Skinny Shot is a compounded medication that is made up of a GLP-1 agonist as well as a supplement called Levocarnitine. The supplement Levocarnitine helps the body mobilize fat and allows the body to utilize stored fat for energy. The GLP-1 agonist helps the body to regulate insulin levels, slows gastric emptying and decreases caloric intake by suppressing appetite.



May 21, 2025 Page | 3

# Tirzepatide is the breakthrough FDA approved medication

## NEW FDA APPROVED DIABETES MEDICATION

Tirzepatide is the breakthrough FDA approved medication that has taken the weight loss industry by storm. This cutting edge medication works similarly to Semaglutide by mimicking the natural body hormones GIP and GLP-1. Get generic Tirzepatide for a fraction of the price.

Compounded GLP-1 Medications, which are often inaccurately described as "generic" versions of semaglutide or tirzepatide, are **not** approved by the FDA. The FDA has **not** approved semaglutide or tirzepatide injections that contain vitamin additives, nor are there any clinical trials of such drug combinations. The FDA has **not** approved any oral formulations of GLP-1 Medications to treat obesity, and oral GLP-1 medications manufactured by compounding pharmacies have not been shown to deliver safe or effective doses of semaglutide or tirzepatide. Importantly, the FDA has approved GLP-1 Medications only for chronic weight management in adults with diagnoses of either obesity or overweight *and* a weight-related comorbidity (e.g. hypertension, type 2 diabetes). GLP-1 Medications are not FDA-approved for cosmetic purposes.

I am sending this letter to raise awareness that the conduct described herein could violate the Connecticut Unfair Trade Practices Act, Conn. Gen. Stat. § 41-110b *et seq.* Your receipt of this letter does not mean that you have engaged in such conduct, or that my office is currently investigating you or your business. The Office of the Attorney General is, however, prepared to take appropriate action against businesses and individuals who continue to engage in the unfair and deceptive conduct described above.

Very truly yours,

WILLIAM TONG